Gene Therapy vs ASO Therapy
Gene therapy usually tries to deliver a genetic payload that changes what cells can produce over a longer period of time. ASO therapy usually works at the RNA level and often needs repeat dosing. Both can be powerful. The right choice depends on the disease mechanism, the target tissue, the size of the gene, whether too much or too little protein is the problem, and how much control clinicians need after treatment begins.
Plain-English explanation
Gene therapy usually tries to deliver a genetic payload that changes what cells can produce over a longer period of time. ASO therapy usually works at the RNA level and often needs repeat dosing. Both can be powerful. The right choice depends on the disease mechanism, the target tissue, the size of the gene, whether too much or too little protein is the problem, and how much control clinicians need after treatment begins.
Why it matters
Families often hear these platforms discussed together, but they are not interchangeable. A one-time gene therapy may sound attractive, but delivery, immune response, and reversibility matter. An ASO may require ongoing treatment, but it can sometimes be adjusted, stopped, or redesigned as researchers learn more.
How it works
Gene therapy generally acts by adding, replacing, editing, or regulating genetic instructions, often using a vector. ASO therapy acts by binding RNA after a gene has been copied but before the cell finishes using that message. In simple terms: gene therapy often changes the source instructions or adds a new instruction; ASOs often edit or silence the working copy.
Key terms
Related interviews and articles
Dr. Guoping Feng (MIT) on SHANK3 Gene Therapy, Brain Disorders, and What’s Coming Next
Dr. Guoping Feng
Welcome — I’m Ron Kleiman, and this is GENEration Hope. In this episode, I’m joined by Dr. Guoping Feng, Professor of Neuroscience at MIT, affiliated with the McGovern Institute, the Yang Tan Collective, and the Broad Institute. 
Inside the Fight to Cure Rett Syndrome – Monica Coenraads Interview
Monica Coenraads
Monica Coenraads, founder and CEO of the Rett Syndrome Research Trust (RSRT), has led the charge to cure Rett Syndrome—raising over $123 million and driving multiple gene therapy programs now in clinical trials. In this in-depth conversa...
What AI Drug Discovery Could Mean for Rare Disease Families
AI drug discovery is entering a new phase: not just better software, but a new industrial stack linking frontier models, pharma data, robotics, and real experiments.
Why it matters: Rare disease research often starts with small datasets, limited funding, urgent timelines, and difficult trial design. AI-linked discovery systems could help researchers generate stronger candidates and better experiments faster, but families should watch for clinical validation, access, manufacturing, and clear evidence rather than hype.
Source: GENEration Hope editorial analysis